KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Charles River Laboratories International (CRL) Accumulated Depreciation & Amortization (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Accumulated Depreciation & Amortization data on record, last reported at $403.3 million in Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 11.49% year-over-year to $403.3 million; the TTM value through Dec 2025 reached $403.3 million, up 11.49%, while the annual FY2025 figure was $403.3 million, 11.49% up from the prior year.
  • Accumulated Depreciation & Amortization reached $403.3 million in Q4 2025 per CRL's latest filing, up from $85.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $403.3 million in Q4 2025 and bottomed at $85.2 million in Q3 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $203.0 million, with a median of $120.4 million recorded in 2025.
  • The widest YoY moves for Accumulated Depreciation & Amortization: up 41.01% in 2025, down 3.44% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $265.5 million in 2021, then rose by 14.43% to $303.9 million in 2022, then grew by 3.37% to $314.1 million in 2023, then grew by 15.16% to $361.7 million in 2024, then increased by 11.49% to $403.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $403.3 million in Q4 2025, $85.2 million in Q3 2025, and $119.5 million in Q2 2025.